crisprtx.com (CRSP) - Cash on Hand per Share

The weak current cash generation of CRISPR Therapeutics AG (CRSP) still relies on partner payments. Cash per share reflects liquidity dynamics, where 23.37 characterizes this valuation parameter. However, expansion into CAR-T therapy and Casgevy mitigates risks, while its status as the unrivaled standard of care for DNA pathologies ensures long-term patent-driven superprofits for the company.
Comprehensive metric breakdowns and analytics for CRISPR Therapeutics Inc (CRSP)

To build a defensive portfolio, fundamental screening relies on the volume of liquid assets divided by the number of shares, which determines the actual cash reserve per share. In the case of CRISPR Therapeutics AG (CRSP), this cash-per-share metric reflects the ability to fund laboratory robotization and automated modification screening, ensuring financial stability during the accelerated rollout of innovations.